Deals: Page 88

  • Image attribution tooltip
    Getty
    Image attribution tooltip

    The Pfizer-AstraZeneca deal is a no-go

    Very few observers had expected the Pfizer-AstraZeneca deal to move forward by the Monday deadline. AstraZeneca has confirmed its intention to remain independent, while Pfizer maintains that its offer was "compelling."

    By • May 27, 2014
  • Image attribution tooltip
    Flickr, Steve Hooton
    Image attribution tooltip

    Novartis will market Fovista for wet AMD outside of the U.S.

    The company is partnering with Ophthotech Corp. in a deal worth $1 billion.

    By • May 21, 2014
  • Image attribution tooltip
    imelenchon
    Image attribution tooltip

    AstraZeneca rejects latest Pfizer takeover bid

    A hostile takeover attempt is not planned, Pfizer says.

    By • May 21, 2014
  • Image attribution tooltip
    Idea go
    Image attribution tooltip

    Valeant continues pursuit of Allergan, ponders company break-up

    Although Allergan has rejected Valeant's latest $47 billion offer, CEO Michael Pearson continues to pursue the acquisition.

    By • May 21, 2014
  • Image attribution tooltip
    The Javorac
    Image attribution tooltip

    Novartis to maintain Gleevec exclusivity until early 2016

    The company has successfully defended its patent for Gleevec (imatanib mesylate) after months of litigation with Sun Pharma.

    By • May 20, 2014
  • Image attribution tooltip
    victor san martin [CC BY-SA 2.0 (https://creativecommons.org/licenses/by-sa/2.0)], from Wikimedia Commons
    Image attribution tooltip

    Abbott seals deal to buy South American pharma company

    Abbott is buying CFR Pharmaceuticals in Chile, with the goal of growing its portfolio, capacity and growth rate.

    By • May 19, 2014